Neil Johnson, PhDFox Chase Cancer Center Investigating the ability of splicing inhibitors to target BRCA1 mutant ovarian cancer Though patients with mutations in the BRCA1 gene respond better to cisplatin and PARP inhibitors than patients without mutations, resistance to these drugs remains a major obstacle for the successful long-term treatment of ovarian cancer. Dr. Johnson’s […]
Read More
Nadine Hempel, PhDPennsylvania State University College of Medicine Pre-clinical Investigation of High Dose Ascorbate IP Therapy High dose of Ascorbate, or Vitamin C, administered through the bloodstream has been suggested to have anti-tumor properties when given in combination with chemotherapy and/or radiotherapy. This concomitant treatment strategy has shown promise in early clinical trials of ovarian […]
Read More
Alan D’Andrea, MDDana-Farber Cancer Institute Novel mechanisms of PARP-inhibitor resistance in BRCA2-deficient ovarian and breast cancer PARP inhibitors are a promising class of drugs for the treatment of ovarian cancers with defects in the BRCA1 or BRCA2 genes. However, drug resistance to PARP inhibitors poses a significant challenge for clinicians. Dr. D’Andrea’s group has recently […]
Read More
Alice Soragni, Ph.D. University of California, Los Angeles Los Angeles, CA, United States 2018 LYNDA’S FUND PILOT STUDY AWARD Project: p53 aggregation in pre-malignant ovarian cancer lesions Research Area: Cancer Biology Summary:p53 is a crucial tumor suppressor protein that prevents damaged cells from becoming cancerous. In order to divide uncontrollably, cancer cells often inactivate p53 by mutating it, as […]
Read More
Gianpietro Dotti, M.D.The University of North Carolina at Chapel Hill Targeting B7-H3 in Ovarian Cancer Ovarian cancer is an aggressive type of tumor for which no effective therapy is currently available when the disease comes back after chemotherapy and surgery. This has prompted Dr. Dotti to develop a strategy in which the immune system will […]
Read More
Emanuela Grassilli, Ph.D.Università degli Studi di Milano-Bicocca (University of Milano – Bicocca)Monza, Italy Project: p65BTK as an actionable target in ovarian cancer Research Area: Novel Therapy Summary:Dr. Grassilli proposes to test treatment of ovarian cancer with drugs that target a protein called p65BTK which is expressed by ovarian cancer cells. She recently identified p65BTK as a protein […]
Read More
Steven M Jay, Ph.D.University of Maryland College ParkCollege Park, MD, United States Engineering HER3-targeted ovarian cancer therapy The presence of the HER3 protein on the surface of ovarian cancer cells is associated with worse survival outcomes; therefore, blocking the pro-cancer activity of the HER3 protein may improve survival. Dr. Jay’s lab has developed a new […]
Read More
Alvaro Monteiro, Ph.D.H. Lee Moffitt Cancer Center & Research InstituteTampa, FL, United States Project: Tackling PARP inhibitor resistance through functional proteomics Research Areas: Chemotherapy Resistance Summary:There has been significant progress in ovarian cancer treatment especially with the development and approval of PARP inhibitor drugs. Despite this progress, a sizable percentage of patients do not respond or stop […]
Read More
John Liao, M.D., Ph.D.University of Washington2018 James A. Harting Pilot Study Award Development of a vaccine to prevent serous tubal intraepithelial carcinoma High grade serous ovarian cancer does not originate in the ovary, as once thought, but on the fallopian tube. Precancerous fallopian tube cells (called serous tubal intraepithelial carcinoma or STIC) can go through […]
Read More
Dan Peer, Ph.D.Tel Aviv UniversityTel Aviv, Israel Project: Developing a novel therapeutic modality to chemo-resistance epithelial ovarian cancer. Research Areas: Novel Therapy, Chemotherapy Resistance Summary:Chemotherapy resistance is one of the biggest challenges for the treatment of epithelial ovarian cancer. One promising method to reliably test new anticancer drugs and understand response to chemotherapy is to develop 3-dimentional […]
Read MoreStarting April 1, 2025, the Rivkin Center’s ovarian cancer research funding, global symposium and fundraising activities will continue under the leadership of Ovarian Cancer Research Alliance (OCRA).
